main content start
How do you like the content?
Multiple Myeloma 8m 2s

EHA 2022 Updates : Multiple Myeloma

Published 05 Aug 2022
EHA 2022 saw exciting progress particularly from the perspective of Bispecific Antibodies showing encouraging response rates in relapsed / refractory setting of Multiple Myeloma.
Dr.Mateos shared trial design for MajesTEC-3: randomized, phase 3 study which will compare teclistamab plus daratumumab versus DPD or DVD in patients with relapsed/refractory multiple myeloma.
MajesTEC -1: trial results for teclistamab (a bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 receptors) showed deep and durable responses in patients with highly refractory MM.
MagnetisMM-1: Clinical trial for elranatamab (BCMA-targeting bispecific antibody) showed an overall response rate of 54% in relapsed or refractory multiple myeloma.
Patients treated with newer immunotherapies have shown an emergence of infections like Pneumocystis jirovecii pneumonia (PJP) & CMV reactivation hence comprehensive infection management measures would be necessary for patients being treated with these therapies.
bcma targeting bispecific antibodies pneumocystis jirovecii pneumonia

Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.

Perks of registering with us
Access to Online/Offline Events
Personalized Content
Access to all Features
Hi, can I help?
Chat SupportX
Support Team
Hello, how can I help you today?
Please select one of the below options.

Find Information

Unable to Login or Register

Want to share feedback